ANI Pharmaceuticals (NASDAQ:ANIP) SVP Sells $133,652.80 in Stock

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) SVP Krista Davis sold 1,622 shares of the business’s stock in a transaction dated Thursday, December 18th. The shares were sold at an average price of $82.40, for a total transaction of $133,652.80. Following the transaction, the senior vice president directly owned 58,564 shares in the company, valued at approximately $4,825,673.60. The trade was a 2.69% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink.

ANI Pharmaceuticals Trading Up 0.0%

Shares of ANI Pharmaceuticals stock traded up $0.02 during mid-day trading on Friday, hitting $82.85. The stock had a trading volume of 965,139 shares, compared to its average volume of 378,840. The firm has a market cap of $1.86 billion, a P/E ratio of 50.83 and a beta of 0.48. ANI Pharmaceuticals, Inc. has a 12-month low of $52.74 and a 12-month high of $99.50. The company has a quick ratio of 2.04, a current ratio of 2.58 and a debt-to-equity ratio of 1.20. The firm has a 50-day moving average of $86.84 and a two-hundred day moving average of $81.20.

ANI Pharmaceuticals (NASDAQ:ANIP) last posted its earnings results on Friday, November 7th. The specialty pharmaceutical company reported $2.04 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.74 by $0.30. ANI Pharmaceuticals had a return on equity of 26.73% and a net margin of 4.91%.The company had revenue of $227.81 million during the quarter, compared to analysts’ expectations of $211.92 million. During the same quarter last year, the firm earned $1.34 earnings per share. The firm’s quarterly revenue was up 53.6% compared to the same quarter last year. ANI Pharmaceuticals has set its FY 2025 guidance at 7.370-7.640 EPS. Sell-side analysts forecast that ANI Pharmaceuticals, Inc. will post 3.86 earnings per share for the current year.

Analyst Ratings Changes

A number of research analysts have commented on ANIP shares. Guggenheim upped their target price on shares of ANI Pharmaceuticals from $114.00 to $115.00 and gave the company a “buy” rating in a research report on Monday, November 10th. Weiss Ratings downgraded shares of ANI Pharmaceuticals from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Monday. Barclays began coverage on shares of ANI Pharmaceuticals in a research report on Tuesday, December 9th. They set an “overweight” rating and a $100.00 price objective for the company. Truist Financial lifted their target price on shares of ANI Pharmaceuticals from $77.00 to $90.00 and gave the company a “hold” rating in a report on Thursday, October 9th. Finally, HC Wainwright upped their price target on ANI Pharmaceuticals from $93.00 to $121.00 and gave the stock a “buy” rating in a research note on Wednesday, September 17th. One investment analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and two have assigned a Hold rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $102.14.

Institutional Trading of ANI Pharmaceuticals

Large investors have recently modified their holdings of the stock. Arrowstreet Capital Limited Partnership acquired a new stake in shares of ANI Pharmaceuticals in the third quarter valued at $32,992,000. Balyasny Asset Management L.P. increased its holdings in ANI Pharmaceuticals by 2,785.7% during the 3rd quarter. Balyasny Asset Management L.P. now owns 286,149 shares of the specialty pharmaceutical company’s stock worth $26,211,000 after purchasing an additional 276,233 shares during the period. Divisadero Street Capital Management LP purchased a new stake in ANI Pharmaceuticals during the 3rd quarter worth about $21,454,000. Rubric Capital Management LP raised its position in ANI Pharmaceuticals by 354.7% in the 2nd quarter. Rubric Capital Management LP now owns 257,669 shares of the specialty pharmaceutical company’s stock valued at $16,813,000 after purchasing an additional 200,998 shares in the last quarter. Finally, UBS Group AG boosted its stake in shares of ANI Pharmaceuticals by 45.8% in the 3rd quarter. UBS Group AG now owns 589,874 shares of the specialty pharmaceutical company’s stock valued at $54,032,000 after buying an additional 185,172 shares during the period. Hedge funds and other institutional investors own 76.05% of the company’s stock.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.